Finally, Pernas et al. reported the analysis of intrinsic tumor subtypes and residual tumors following neoadjuvant trastuzumab-based chemotherapy in a group of 150 patients with stage II-IIIC HER2-positive breast cancers [90]. Here, ERBB2 is linked to breast cancer.